ClinConnect ClinConnect Logo
Search / Trial NCT00804973

Study in Participants With Acute Migraines Headaches

Launched by ELI LILLY AND COMPANY · Dec 5, 2008

Trial Information

Current as of May 22, 2025

Terminated

Keywords

Migraine Headache

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and female participants between the ages of 18 and 65 years, inclusive.
  • Participants who have migraine headaches, with or without aura (diagnosis according the International Classification of Headache Disorders-II), for at least 1 year.
  • Participants who have had 2-8 migraine attacks on average per month for the last 3 months (but less than 15 headache days per month).
  • Participants who are willing and able to comply with the study schedule and requirements.
  • Participants who speak, read, and understand English sufficiently well and are willing to provide written informed consent.
  • Participants who in the opinion of the principal investigator are in good general health.
  • Venous access should be sufficient to allow blood sampling as per protocol.
  • Exclusion Criteria:
  • Participants who do not or may not tolerate 5HT1 agonist treatments, with known hypersensitivity to sumatriptan (as discussed with the investigator).
  • Female participants who have a positive pregnancy test at screening or pre- dose evaluation, or are breastfeeding.
  • History or presence of significant medical illnesses as determined by the investigator.
  • Participants with a current clinical diagnosis of major psychiatric disease.
  • Regular use of known drugs of abuse; use of opiates for migraine rescue (no more than two times per month) is permissible.
  • Blood donation of 500 milliliter (mL) or greater of whole blood products within 4 weeks of study commencement, during the study, or 4 weeks following the study.
  • Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Consumption of more than three units of alcohol per day where one unit is defined as a 12 ounces (oz) beer, 4 oz wine, or 2 oz of alcohol spirit liquor.
  • Are unwilling or unable to comply with the use of a diary to directly record data from the participant.

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

San Diego, California, United States

Norfolk, Virginia, United States

Beverly Hills, California, United States

Fresno, California, United States

Memphis, Tennessee, United States

Garden Grove, California, United States

Philadelphia, Pennsylvania, United States

West Palm Beach, Florida, United States

Philadelphia, Pennsylvania, United States

Santa Monica, California, United States

Ann Arbor, Michigan, United States

San Francisco, California, United States

Wellesley Hills, Massachusetts, United States

Chula Vista, California, United States

Imperial, California, United States

Chicago, Illinois, United States

Mount Vernon, New York, United States

West Chester, Ohio, United States

Austin, Texas, United States

Houston, Texas, United States

Patients applied

0 patients applied

Trial Officials

Call 1-877-CTLILLY or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials